{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T06:55:48Z","timestamp":1760424948002},"reference-count":70,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1016\/j.schres.2009.02.017","type":"journal-article","created":{"date-parts":[[2009,3,10]],"date-time":"2009-03-10T09:35:50Z","timestamp":1236677750000},"page":"80-89","source":"Crossref","is-referenced-by-count":22,"title":["Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: The MOZART study"],"prefix":"10.1016","volume":"110","author":[{"given":"Emilio","family":"Sacchetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Galluzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Valsecchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Romeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Gorini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lewis","family":"Warrington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2009.02.017_bib1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0920-9964(90)90005-R","article-title":"A depression rating scale for schizophrenics","volume":"3","author":"Addington","year":"1990","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2009.02.017_bib2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0920-9964(92)90003-N","article-title":"Reliability and validity of a depression rating scale for schizophrenics","volume":"6","author":"Addington","year":"1992","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2009.02.017_bib3","series-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)","author":"American Psychiatric Association","year":"1994"},{"key":"10.1016\/j.schres.2009.02.017_bib4","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.4088\/JCP.v65n1007","article-title":"Insulin resistance and increased leptin concentration in noncompliant schizophrenia patient but not in antipsychotic-na\u00efve first-episode schizophrenia patients","volume":"65","author":"Arranz","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2009.02.017_bib5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1600-0447.1994.tb05828.x","article-title":"Subjective response to neuroleptics and the quality of life: implications for treatment outcome","volume":"380","author":"Awad","year":"1994","journal-title":"Acta Psychiatr. Scand., Suppl."},{"key":"10.1016\/j.schres.2009.02.017_bib6","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1176\/appi.ajp.158.8.1305","article-title":"A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia","volume":"158","author":"Azorin","year":"2001","journal-title":"Am. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2009.02.017_bib7","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2165\/00023210-200822060-00003","article-title":"Pharmacological management of atypical antipsychotic-induced weight gain","volume":"22","author":"Baptista","year":"2008","journal-title":"CNS Drugs"},{"key":"10.1016\/j.schres.2009.02.017_bib8","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2009.02.017_bib9","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.pnpbp.2003.09.033","article-title":"Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia","volume":"28","author":"Bitter","year":"2004","journal-title":"Prog. Neuro-psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2009.02.017_bib10","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1176\/ajp.155.4.499","article-title":"Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study","volume":"155","author":"Bondolfi","year":"1998","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2009.02.017_bib11","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1176\/ajp.156.2.294","article-title":"Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response","volume":"156","author":"Breier","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2009.02.017_bib12","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1176\/appi.ajp.158.4.518","article-title":"Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials","volume":"158","author":"Chakos","year":"2001","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2009.02.017_bib13","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1177\/070674370805300407","article-title":"Lifestyle characteristics of psychiatric outpatients","volume":"53","author":"Chuang","year":"2008","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.schres.2009.02.017_bib14","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S0006-3223(01)01271-9","article-title":"Management of treatment resistance in schizophrenia","volume":"50","author":"Conley","year":"2001","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2009.02.017_bib15","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/01.jcp.0000096246.29231.73","article-title":"The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study","volume":"23","author":"Conley","year":"2003","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2009.02.017_bib16","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.schres.2008.01.028","article-title":"Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review","volume":"101","author":"De Hert","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2009.02.017_bib17","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.psc.2007.04.001","article-title":"Treatment-resistant schizophrenia","volume":"30","author":"Elkis","year":"2007","journal-title":"Psychiatr. Clin. North Am."},{"key":"10.1016\/j.schres.2009.02.017_bib18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/schbul\/22.1.15","article-title":"Clozapine eligibility among state hospital patients","volume":"22","author":"Essock","year":"1996","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2009.02.017_bib19","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1176\/ps.47.12.1356","article-title":"Mortality and medical comorbidity among psychiatric patients: a review","volume":"47","author":"Felker","year":"1996","journal-title":"Psychiatr. Serv."},{"issue":"suppl 6","key":"10.1016\/j.schres.2009.02.017_bib20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1177\/0269881105058380","article-title":"Clustering of metabolic comorbidity in schizophrenia: a generic contribution?","volume":"19","author":"Gough","year":"2005","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.schres.2009.02.017_bib21","series-title":"ECDEU Assessment Manual for Psychopharmacology.","first-page":"76","author":"Guy","year":"1976"},{"key":"10.1016\/j.schres.2009.02.017_bib22","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.schres.2007.11.014","article-title":"A randomized double-blind comparison of ziprasidone vs. clozapine for cognition in patients with schizophrenia selected for resistance or intolerance to previous treatment","volume":"105","author":"Harvey","year":"2008","journal-title":"Schizophr. Res."},{"issue":"supp 3","key":"10.1016\/j.schres.2009.02.017_bib23","doi-asserted-by":"crossref","first-page":"s149","DOI":"10.1016\/j.euroneuro.2006.06.003","article-title":"Differential metabolic effect of antipsychotic treatments","volume":"16","author":"Haupt","year":"2006","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"suppl.6","key":"10.1016\/j.schres.2009.02.017_bib24","first-page":"11","article-title":"Schizophrenia and comorbid metabolic disorders","volume":"66","author":"Henderson","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2009.02.017_bib25","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.4088\/JCP.v66n0905","article-title":"Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-years naturalistic study","volume":"66","author":"Henderson","year":"2005","journal-title":"J. Clin. Psychiatry"},{"issue":"Suppl 19","key":"10.1016\/j.schres.2009.02.017_bib26","first-page":"19","article-title":"Oral ziprasidone in the treatment of schizophrenia: a review of short-term trials","volume":"64","author":"Kane","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2009.02.017_bib27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/01.yic.0000182114.65134.81","article-title":"Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia","volume":"21","author":"Kane","year":"2006","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2009.02.017_bib28","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2009.02.017_bib29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0165-1781(88)90038-8","article-title":"Reliability and validity of the positive and negative syndrome scale for schizophrenics","volume":"23","author":"Kay","year":"1988","journal-title":"Psychiatry Res."},{"issue":"suppl.47","key":"10.1016\/j.schres.2009.02.017_bib30","doi-asserted-by":"crossref","first-page":"s64","DOI":"10.1192\/bjp.184.47.s64","article-title":"Diabetes mellitus and schizophrenia: historical perspective","volume":"184","author":"Kohen","year":"2004","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2009.02.017_bib31","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1001\/archpsyc.1979.01780040056006","article-title":"Morbidity and rate of undiagnosed physical illnesses in a psychiatric clinic population","volume":"36","author":"Koranyi","year":"1979","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2009.02.017_bib32","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1176\/ajp.2006.163.7.1273","article-title":"Prevalence of the metabolic syndrome among patients receiving clozapine","volume":"163","author":"Lamberti","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2009.02.017_bib33","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.pnpbp.2003.09.024","article-title":"Combination of \u201catypical\u201d antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder","volume":"28","author":"Lerner","year":"2004","journal-title":"Prog. Neuro-psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2009.02.017_bib34","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1600-0447.2007.01095.x","article-title":"Physical illness and schizophrenia: a review of literature","volume":"116","author":"Leucht","year":"2007","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2009.02.017_bib35","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2009.02.017_bib36","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.schres.2009.02.017_bib37","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.schres.2006.08.008","article-title":"Lack of care for diabetes among schizophrenia patients","volume":"89","author":"Lin","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2009.02.017_bib38","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1023\/A:1004640408501","article-title":"Treatment refractory schizophrenia","volume":"71","author":"Lindenmayer","year":"2000","journal-title":"Psychiatr. Q."},{"key":"10.1016\/j.schres.2009.02.017_bib39","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1176\/appi.ajp.160.2.290","article-title":"Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics","volume":"160","author":"Lindenmayer","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2009.02.017_bib40","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.4088\/JCP.v68n0902","article-title":"Ziprasidone in treatment-resistant schizophrenia: a 52-week, open-label continuation study","volume":"68","author":"Loebel","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2009.02.017_bib41","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1176\/appi.ajp.161.8.1334","article-title":"Physical health monitoring of patients with schizophrenia","volume":"161","author":"Marder","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2009.02.017_bib42","first-page":"534","article-title":"Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study","volume":"183","author":"McCreadie","year":"2003","journal-title":"Br. J. Psychiatry"},{"issue":"suppl 14","key":"10.1016\/j.schres.2009.02.017_bib43","first-page":"4","article-title":"The cost of schizophrenia","volume":"68","author":"McEvoy","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2009.02.017_bib44","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.schres.2005.07.014","article-title":"Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III","volume":"80","author":"McEvoy","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2009.02.017_bib45","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1176\/ajp.2006.163.4.600","article-title":"Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment","volume":"163","author":"McEvoy","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2009.02.017_bib46","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.schres.2007.12.487","article-title":"Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE schizophrenia trial: prospective data from phase 1","volume":"101","author":"Meyer","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2009.02.017_bib47","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1055\/s-2007-979481","article-title":"Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study","volume":"30","author":"Meyer-Lindenberg","year":"1997","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.schres.2009.02.017_bib48","doi-asserted-by":"crossref","first-page":"s121","DOI":"10.1016\/j.euroneuro.2008.02.002","article-title":"Management of physical health in schizophrenia: a stepping stone to treatment success","volume":"18","author":"Millar","year":"2008","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2009.02.017_bib49","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1192\/bjp.183.2.161","article-title":"Clozapine v. conventional antipsychotic drugs for treatment-resistant schizophrenia: a re-examination","volume":"183","author":"Moncrieff","year":"2003","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2009.02.017_bib50","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.pnpbp.2006.10.002","article-title":"Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone","volume":"31","author":"Montes","year":"2007","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2009.02.017_bib51","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/sj.mp.4002066","article-title":"Atypical antipsychotic-induced metabolic side effect: insights from receptor-binding profiles","volume":"13","author":"Nasrallah","year":"2008","journal-title":"Mol. Psychiatry"},{"issue":"suppl.1","key":"10.1016\/j.schres.2009.02.017_bib52","first-page":"1","article-title":"Second-generation (atypical) antispychotics and metabolic effects. A comprehensive literature review","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"issue":"suppl 1","key":"10.1016\/j.schres.2009.02.017_bib53","first-page":"20","article-title":"Metabolic considerations in the use of antipsychotic medications: a review of recent evidence","volume":"68","author":"Newcomer","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2009.02.017_bib54","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1517\/14656566.1.2.249","article-title":"The new atypical antipsychotics: a review of pharmacoeconomic studies","volume":"1","author":"Revicki","year":"2000","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.schres.2009.02.017_bib55","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1176\/appi.ajp.160.2.284","article-title":"Impaired fasting glucose and elevation of cortisol elevation in drug-na\u00efve first episode schizophrenia","volume":"160","author":"Ryan","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2009.02.017_bib56","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.lfs.2003.08.044","article-title":"The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-na\u00efve patients with schizophrenia","volume":"74","author":"Ryan","year":"2004","journal-title":"Life Sci."},{"key":"10.1016\/j.schres.2009.02.017_bib57","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0920-9964(03)00225-1","article-title":"Quetiapine in hospitalized patients with schizophrenia refractory to treatment with first-generation antipsychotics: a 4-week, flexible-dose, single-blind, exploratory, pilot trial","volume":"69","author":"Sacchetti","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2009.02.017_bib70","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.schres.2007.09.011","article-title":"A randomized, flexible-dose, quasi naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial","volume":"98","author":"Sacchetti","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2009.02.017_bib58","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.schres.2008.02.013","article-title":"Are metabolic indices different between drug-na\u00efve first-episode psychosis patients and healthy controls?","volume":"102","author":"Sengupta","year":"2008","journal-title":"Schizophr. Res."},{"issue":"suppl 3","key":"10.1016\/j.schres.2009.02.017_bib59","first-page":"38","article-title":"Side effects as influencers of treatment outcome","volume":"69","author":"Sharif","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2009.02.017_bib60","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr. Scand., Suppl."},{"key":"10.1016\/j.schres.2009.02.017_bib61","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1176\/ajp.161.10.1837","article-title":"Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder","volume":"161","author":"Simpson","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2009.02.017_bib62","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1176\/appi.ajp.162.8.1535","article-title":"Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia","volume":"162","author":"Simpson","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2009.02.017_bib63","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1464-5491.2007.02092.x","article-title":"Impaired glucose tolerance in first-episode drug-na\u00efve patients with schizophrenia","volume":"24","author":"Spelman","year":"2007","journal-title":"Diabet. Med."},{"key":"10.1016\/j.schres.2009.02.017_bib64","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/026988110001400411","article-title":"Refractory schizophrenia and atypical antipsychotics","volume":"14","author":"Taylor","year":"2000","journal-title":"J. Psychopharmacol."},{"issue":"suppl.47","key":"10.1016\/j.schres.2009.02.017_bib65","doi-asserted-by":"crossref","first-page":"s76","DOI":"10.1192\/bjp.184.47.s76","article-title":"Metabolic disturbance in first-episode","volume":"184","author":"Thakore","year":"2004","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2009.02.017_bib66","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0006-3223(00)01026-X","article-title":"Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine","volume":"49","author":"Tollefson","year":"2001","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2009.02.017_bib67","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1176\/appi.ajp.159.2.255","article-title":"Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder","volume":"159","author":"Volavka","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2009.02.017_bib68","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/sj.npp.1301482","article-title":"Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone","volume":"33","author":"Weiden","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2009.02.017_bib69","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/01.wnf.0000183446.58529.30","article-title":"Combination of clozapine and ziprasidone in treatment-resistant schizophrenia: an open clinical study","volume":"28","author":"Ziegenbein","year":"2005","journal-title":"Clin. Neuropharmacol."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996409000838?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996409000838?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T09:17:15Z","timestamp":1684919835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996409000838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":70,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["S0920996409000838"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2009.02.017","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}